Keywords
Last Name
Institution

BONNIE S GLISSON

TitleProfessor
InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Massarelli E, Ferrarotto R, Glisson BS. New Strategies in Human Papillomavirus-Related Oropharynx Cancer: Effecting Advances in Treatment for a Growing Epidemic. Clin Cancer Res. 2015 Sep 1; 21(17):3821-8. PMID: 26330505.
      View in: PubMed
    2. Mazumdar T, Sen B, Wang Y, Peng S, Nicholas C, Glisson BS, Myers JN, Johnson FM. Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers. Anticancer Drugs. 2015 Sep; 26(8):835-42. PMID: 26053277.
      View in: PubMed
    3. Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015 May; 37(5):644-9. PMID: 24585506.
      View in: PubMed
    4. Carter BW, Glisson BS, Truong MT, Erasmus JJ. Small cell lung carcinoma: staging, imaging, and treatment considerations. Radiographics. 2014 Oct; 34(6):1707-21. PMID: 25310425.
      View in: PubMed
    5. Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. Mol Cancer Ther. 2014 Nov; 13(11):2738-50. PMID: 25193510; PMCID: PMC4221385.
    6. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21; 311(19):1998-2006. PMID: 24846037.
      View in: PubMed
    7. Mak MP, Glisson BS. Is there still a role for induction chemotherapy in locally advanced head and neck cancer? Curr Opin Oncol. 2014 May; 26(3):247-51. PMID: 24651382.
      View in: PubMed
    8. Shin DH, Lee HJ, Min HY, Choi SP, Lee MS, Lee JW, Johnson FM, Mehta K, Lippman SM, Glisson BS, Lee HY. Combating resistance to anti-IGFR antibody by targeting the integrin ?3-Src pathway. J Natl Cancer Inst. 2013 Oct 16; 105(20):1558-70. PMID: 24092920; PMCID: PMC3797025.
    9. Gunn GB, Debnam JM, Fuller CD, Morrison WH, Frank SJ, Beadle BM, Sturgis EM, Glisson BS, Phan J, Rosenthal DI, Garden AS. The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. Cancer. 2013 Sep 1; 119(17):3162-9. PMID: 23733178; PMCID: PMC3775996.
    10. Garden AS, Kies MS, Morrison WH, Weber RS, Frank SJ, Glisson BS, Gunn GB, Beadle BM, Ang KK, Rosenthal DI, Sturgis EM. Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiat Oncol. 2013; 8:21. PMID: 23360540; PMCID: PMC3576243.
    11. El-Sawy T, Sabichi AL, Myers JN, Kies MS, William WN, Glisson BS, Lippman S, Esmaeli B. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012 Dec; 130(12):1608-11. PMID: 23229707.
      View in: PubMed
    12. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar 1; 31(7):845-52. PMID: 23182993; PMCID: PMC3577950.
    13. Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, Glisson B, Milas L, Ang KK. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol. 2012 Nov; 105(2):241-9. PMID: 23010482.
      View in: PubMed
    14. Garden AS, Dong L, Morrison WH, Stugis EM, Glisson BS, Frank SJ, Beadle BM, Gunn GB, Schwartz DL, Kies MS, Weber RS, Ang KK, Rosenthal DI. Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):941-7. PMID: 22975604.
      View in: PubMed
    15. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012 Sep; 2(9):798-811. PMID: 22961666; PMCID: PMC3567922.
    16. Dahlstrom KR, Calzada G, Hanby JD, Garden AS, Glisson BS, Li G, Roberts DB, Weber RS, Sturgis EM. An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. Cancer. 2013 Jan 1; 119(1):81-9. PMID: 22736261; PMCID: PMC3469778.
    17. Oh SH, Kim WY, Lee OH, Kang JH, Woo JK, Kim JH, Glisson B, Lee HY. Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma. Cancer Sci. 2012 Jul; 103(7):1259-66. PMID: 22494072; PMCID: PMC3465461.
    18. Komaki R, Paulus R, Ettinger DS, Videtic GM, Bradley JD, Glisson BS, Langer CJ, Sause WT, Curran WJ, Choy H. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e531-6. PMID: 22560543.
      View in: PubMed
    19. Oh SH, Whang YM, Min HY, Han SH, Kang JH, Song KH, Glisson BS, Kim YH, Lee HY. Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation. Int J Cancer. 2012 Nov 15; 131(10):2253-63. PMID: 22362554; PMCID: PMC3627058.
    20. Thariat J, Ang KK, Allen PK, Ahamad A, Williams MD, Myers JN, El-Naggar AK, Ginsberg LE, Rosenthal DI, Glisson BS, Morrison WH, Weber RS, Garden AS. Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2012 Mar 1; 82(3):e367-74. PMID: 22284033; PMCID: PMC4124997.
    21. Kim WY, Prudkin L, Feng L, Kim ES, Hennessy B, Lee JS, Lee JJ, Glisson B, Lippman SM, Wistuba II, Hong WK, Lee HY. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer. 2012 Aug 15; 118(16):3993-4003. PMID: 22359227; PMCID: PMC3674414.
    22. Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA, Weber RS. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Mar 1; 18(5):1435-46. PMID: 22261807.
      View in: PubMed
    23. Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J, Hu K, Le QT, Colevas AD, Glisson BS, Chan AT, Ang KK. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol. 2012 Feb; 13(2):172-80. PMID: 22178121.
      View in: PubMed
    24. Shin DH, Min HY, El-Naggar AK, Lippman SM, Glisson B, Lee HY. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther. 2011 Dec; 10(12):2437-48. PMID: 21980128; PMCID: PMC3237768.
    25. Glisson BS, Moran CA. Large-cell neuroendocrine carcinoma: controversies in diagnosis and treatment. J Natl Compr Canc Netw. 2011 Oct; 9(10):1122-9. PMID: 21975912.
      View in: PubMed
    26. William WN, Glisson BS. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol. 2011 Oct; 8(10):611-9. PMID: 21691321.
      View in: PubMed
    27. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. 2011 May 15; 117(10):2112-9. PMID: 21523723.
      View in: PubMed
    28. Gitlitz BJ, Moon J, Glisson BS, Reimers HJ, Bury MJ, Floyd JD, Schulz TK, Sundaram PK, Ho C, Gandara DR. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010 Nov; 5(11):1835-40. PMID: 20881645; PMCID: PMC3676180.
    29. Stewart DJ, Johnson C, Lopez A, Glisson B, Rhee JM, Bekele BN. Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms. J Thorac Oncol. 2010 Nov; 5(11):1826-34. PMID: 20881640.
      View in: PubMed
    30. Glisson BS. Targeting an autocrine loop in small-cell lung cancer: irrelevant target or ineffective drug? Clin Lung Cancer. 2010 Jul 1; 11(4):222. PMID: 20630822.
      View in: PubMed
    31. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63. PMID: 20530716; PMCID: PMC2913168.
    32. William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 2010 May 15; 116(10):2409-15. PMID: 20225329.
      View in: PubMed
    33. William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol. 2010 Apr; 33(2):148-52. PMID: 19687727.
      View in: PubMed
    34. Frank SJ, Rosenthal DI, Petsuksiri J, Ang KK, Morrison WH, Weber RS, Glisson BS, Chao KS, Schwartz DL, Chronowski GM, El-Naggar AK, Garden AS. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1005-10. PMID: 20207504.
      View in: PubMed
    35. Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 1; 28(1):8-14. PMID: 19917840; PMCID: PMC2799235.
    36. Johnson FM, Glisson BS. Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC? Nat Rev Clin Oncol. 2009 Oct; 6(10):562-3. PMID: 19786998.
      View in: PubMed
    37. Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, Jones C, Ang KK. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009 Aug 1; 27(22):3684-90. PMID: 19564532.
      View in: PubMed
    38. Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Feng L, Tran HT, Ginsberg LE, Truong MT, Hong WK, Kim ES. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2009 Jun; 32(3):274-9. PMID: 19433965.
      View in: PubMed
    39. Holsinger FC, Kies MS, Diaz EM, Gillenwater AM, Lewin JS, Ginsberg LE, Glisson BS, Garden AS, Ark N, Lin HY, Lee JJ, El-Naggar AK, Ki Hong W, Shin DM, Khuri FR. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol. 2009 Apr 20; 27(12):1976-82. PMID: 19289628; PMCID: PMC2738635.
    40. Thariat J, Ahamad A, El-Naggar AK, Williams MD, Holsinger FC, Glisson BS, Allen PK, Morrison WH, Weber RS, Ang KK, Garden AS. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer. 2008 Jun 15; 112(12):2698-709. PMID: 18429002.
      View in: PubMed
    41. Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jan 1; 73(1):119-27. PMID: 18556142.
      View in: PubMed
    42. Sulman EP, Schwartz DL, Le TT, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Kies M, Glisson B, Weber R, Garden AS. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2009 Feb 1; 73(2):399-409. PMID: 18556144.
      View in: PubMed
    43. Saigal B, Glisson BS, Johnson FM. Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma. Anticancer Drugs. 2008 Jun; 19(5):465-75. PMID: 18418213.
      View in: PubMed
    44. William WN, Zinner RG, Karp DD, Oh YW, Glisson BS, Phan SC, Stewart DJ. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol. 2007 Aug; 2(8):745-50. PMID: 17762342.
      View in: PubMed
    45. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 1; 24(25):4163-9. PMID: 16943532.
      View in: PubMed
    46. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31. PMID: 16640804.
      View in: PubMed
    47. Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, Peeples B, Patel J, Glisson BS. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer. 2006 Jan 15; 106(2):366-74. PMID: 16342249.
      View in: PubMed
    48. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005 Dec 1; 104(11):2449-56. PMID: 16258975.
      View in: PubMed
    49. Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri F, Clayman G, Goepfert H, Ang KK, Hong WK, Glisson BS. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2005 Nov 1; 63(3):717-24. PMID: 16199307.
      View in: PubMed
    50. Sturgis EM, Moore BA, Glisson BS, Kies MS, Shin DM, Byers RM. Neoadjuvant chemotherapy for squamous cell carcinoma of the oral tongue in young adults: a case series. Head Neck. 2005 Sep; 27(9):748-56. PMID: 16086413.
      View in: PubMed
    51. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer. 2005 Aug 1; 104(3):561-9. PMID: 16028213.
      View in: PubMed
    52. Komaki R, Swann RS, Ettinger DS, Glisson BS, Sandler AB, Movsas B, Suh J, Byhardt RW. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys. 2005 Jun 1; 62(2):342-50. PMID: 15890573.
      View in: PubMed
    53. Rosenthal DI, Barker JL, El-Naggar AK, Glisson BS, Kies MS, Diaz EM, Clayman GL, Demonte F, Selek U, Morrison WH, Ang KK, Chao KS, Garden AS. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer. 2004 Dec 1; 101(11):2567-73. PMID: 15517582.
      View in: PubMed
    54. Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2004 Jul 15; 22(14):2856-64. PMID: 15254053.
      View in: PubMed
    55. Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, Kantarjian H, Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res. 2004 Jun; 28(6):657-60. PMID: 15120945.
      View in: PubMed
    56. Tsao AS, Shin DM, Palmer JL, Lee JS, Glisson BS. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Cancer. 2004 May 15; 100(10):2240-5. PMID: 15139070.
      View in: PubMed
    57. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res. 2004 May 1; 10(9):2968-76. PMID: 15131032.
      View in: PubMed
    58. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 1; 58(5):1369-77. PMID: 15050312.
      View in: PubMed
    59. Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer. 2004 Apr; 44(1):99-110. PMID: 15013588.
      View in: PubMed
    60. Garden AS, Asper JA, Morrison WH, Schechter NR, Glisson BS, Kies MS, Myers JN, Ang KK. Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer. 2004 Mar 15; 100(6):1171-8. PMID: 15022283.
      View in: PubMed
    61. Johnson FM, Garden A, Palmer JL, Kies M, Clayman G, Brumfield B, Khuri FR, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer. 2004 Mar 1; 100(5):991-8. PMID: 14983495.
      View in: PubMed
    62. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, Costello R, Summey C, Arquette M, Langer C, Amrein PC, Posner M. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004 Feb 1; 10(3):944-6. PMID: 14871971.
      View in: PubMed
    63. Barker JL, Glisson BS, Garden AS, El-Naggar AK, Morrison WH, Ang KK, Chao KS, Clayman G, Rosenthal DI. Management of nonsinonasal neuroendocrine carcinomas of the head and neck. Cancer. 2003 Dec 1; 98(11):2322-8. PMID: 14635065.
      View in: PubMed
    64. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003 Nov 27; 349(22):2091-8. PMID: 14645636.
      View in: PubMed
    65. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, Kies MS, Glisson BS, Diaz EM, Clayman G, Morrison WH, Liu DD, Blumenschein G, Lippman SM, Schommer D, Gillenwater A, Goepfert H, Hong WK. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer. 2003 Nov 15; 98(10):2214-23. PMID: 14601092.
      View in: PubMed
    66. Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003 Oct; 39(7):724-7. PMID: 12907212.
      View in: PubMed
    67. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5. PMID: 14596703.
      View in: PubMed
    68. Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):17-21. PMID: 12886869.
      View in: PubMed
    69. Lu C, Komaki R, Lee JS, Shin DM, Palmer JL, Coldman BJ, Pisters KM, Kurie JM, Fossella FV, Glisson BS. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res. 2003 Jun; 9(6):2085-91. PMID: 12796372.
      View in: PubMed
    70. Glisson BS. Recurrent small cell lung cancer: update. Semin Oncol. 2003 Feb; 30(1):72-8. PMID: 12635091.
      View in: PubMed
    71. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101. PMID: 12538456.
      View in: PubMed
    72. Kim ES, Glisson BS. Treatment of metastatic head and neck cancer: chemotherapy and novel agents. Cancer Treat Res. 2003; 114:295-314. PMID: 12619547.
      View in: PubMed
    73. Weber RS, Berkey BA, Forastiere A, Cooper J, Maor M, Goepfert H, Morrison W, Glisson B, Trotti A, Ridge JA, Chao KS, Peters G, Lee DJ, Leaf A, Ensley J. Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg. 2003 Jan; 129(1):44-9. PMID: 12525193.
      View in: PubMed
    74. Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers J, Clayman G, Hong WK. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2002 Jul 15; 95(2):322-30. PMID: 12124833.
      View in: PubMed
    75. Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53. PMID: 12124835.
      View in: PubMed
    76. Stein CK, Glover TW, Palmer JL, Glisson BS. Direct correlation between FRA3B expression and cigarette smoking. Genes Chromosomes Cancer. 2002 Jul; 34(3):333-40. PMID: 12007194.
      View in: PubMed
    77. Villaret D, Glisson B, Kenady D, Hanna E, Carey M, Gleich L, Yoo GH, Futran N, Hung MC, Anklesaria P, Heald AE. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck. 2002 Jul; 24(7):661-9. PMID: 12112540.
      View in: PubMed
    78. Glisson BS. The role of docetaxel in the management of squamous cell cancer of the head and neck. Oncology (Williston Park). 2002 Jun; 16(6 Suppl 6):83-7. PMID: 12108901.
      View in: PubMed
    79. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2002 Mar 15; 20(6):1593-9. PMID: 11896109.
      View in: PubMed
    80. Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002 Jan 15; 20(2):364-70. PMID: 11786562.
      View in: PubMed
    81. Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol. 2002 Jan; 12(1 Suppl 1):46-9. PMID: 11917284.
      View in: PubMed
    82. Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, Liu D, Jung M, Hong WK, Herbst RS. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer. 2001 Dec; 34(3):427-32. PMID: 11714540.
      View in: PubMed
    83. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001 Nov 1; 92(9):2364-73. PMID: 11745292.
      View in: PubMed
    84. Herbst RS, Khuri FR, Fossella FV, Glisson BS, Kies MS, Pisters KM, Riddle JR, Terry KA, Lee JS. ZD1839 (Iressa) in non-small-cell lung cancer. Clin Lung Cancer. 2001 Aug; 3(1):27-32. PMID: 14656386.
      View in: PubMed
    85. Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, Liu D, Glisson BS, Ginsberg L, Papadimitrakopoulou V, Myers J, Morrison W, Gillenwater A, Ang KK, Lippman SM, Goepfert H, Hong WK. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol. 2001 Jun 15; 19(12):3010-7. PMID: 11408495.
      View in: PubMed
    86. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001 May; 7(5):1204-13. PMID: 11350885.
      View in: PubMed
    87. Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, Lee JJ, Ang KK, Lippman SM, Hong WK. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer. 2001 Apr 1; 91(7):1316-23. PMID: 11283932.
      View in: PubMed
    88. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, Glisson BS, Lee JS. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol. 2001 Mar 15; 19(6):1830-8. PMID: 11251015.
      View in: PubMed
    89. Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, Seroskie JD, Shin DM, Olivares R, Garay CA. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001 Feb 15; 19(4):1096-104. PMID: 11181674.
      View in: PubMed
    90. Glisson B, Scott C, Komaki R, Movsas B, Wagner H. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12. J Clin Oncol. 2000 Aug; 18(16):2990-5. PMID: 10944132.
      View in: PubMed
    91. Khuri FR, Shin DM, Glisson BS, Lippman SM, Hong WK. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin Oncol. 2000 Aug; 27(4 Suppl 8):25-33. PMID: 10952435.
      View in: PubMed
    92. Oh Y, Perez-Soler R, Fossella FV, Glisson BS, Kurie J, Walsh GL, Truong M, Shin DM. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs. 2000 Aug; 18(3):243-5. PMID: 10958592.
      View in: PubMed
    93. Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, Perez-Soler R, Pisters KM, Putnam JB, Schrump DS, Shin DM, Walsh GL, Roth JA. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther. 2000 Apr; 7(4):530-6. PMID: 10811470.
      View in: PubMed
    94. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 2000 Feb; 18(3):609-22. PMID: 10653876.
      View in: PubMed
    95. Glisson BS, Kurie JM, Perez-Soler R, Fox NJ, Murphy WK, Fossella FV, Lee JS, Ross MB, Nyberg DA, Pisters KM, Shin DM, Hong WK. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol. 1999 Aug; 17(8):2309-15. PMID: 10561292.
      View in: PubMed
    96. Garden AS, Glisson BS, Ang KK, Morrison WH, Lippman SM, Byers RM, Geara F, Clayman GL, Shin DM, Callender DL, Khuri FR, Goepfert H, Hong WK, Peters LJ. Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses. J Clin Oncol. 1999 Aug; 17(8):2390-5. PMID: 10561301.
      View in: PubMed
    97. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 May 5; 91(9):763-71. PMID: 10328106.
      View in: PubMed
    98. Lee JS, Komaki R, Fossella FV, Glisson BS, Hong WK, Cox JD. A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report. Int J Radiat Oncol Biol Phys. 1998 Oct 1; 42(3):479-86. PMID: 9806504.
      View in: PubMed
    99. Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossella FV, Glisson BS, Hong WK, Khurl FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump DS, Shin DM, Walsh GL. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol. 1998 Jun; 25(3 Suppl 8):33-7. PMID: 9704675.
      View in: PubMed
    100. Shin DM, Glisson BS, Khuri FR, Hong WK, Lippman SM. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol. 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PMID: 9578061.
      View in: PubMed
    101. Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, Lawhorn K, Gillenwater AM, Ang KK, Clayman GL, Callender DL, Hong WK, Lippman SM. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998 Apr; 16(4):1325-30. PMID: 9552033.
      View in: PubMed
    102. Khuri FR, Fossella FV, Lee JS, Murphy WK, Shin DM, Markowitz AB, Glisson BS. Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer. J Interferon Cytokine Res. 1998 Apr; 18(4):241-5. PMID: 9568726.
      View in: PubMed
    103. Brockstein B, Haraf DJ, Stenson K, Fasanmade A, Stupp R, Glisson B, Lippman SM, Ratain MJ, Sulzen L, Klepsch A, Weichselbaum RR, Vokes EE. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44. PMID: 9469365.
      View in: PubMed
    104. Glisson B, Lee JS, Palmer J, Fossella F, Shin DM, Murphy WK, Perez-Soler R, Hong WK. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma. Cancer. 1998 Jan 15; 82(2):301-8. PMID: 9445186.
      View in: PubMed
    105. Glisson B, Komaki R, Lee JS, Shin DM, Fossella F, Murphy WK, Kurie J, Perez-Soler R, Schea R, Vadhan-Raj S. Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):331-6. PMID: 9457817.
      View in: PubMed
    106. Shade RJ, Pisters KM, Huber MH, Fossella F, Perez-Soler R, Shin DM, Kurie J, Glisson B, Lippman S, Lee JS. Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs. 1998-1999; 16(3):237-43. PMID: 10360603.
      View in: PubMed
    107. Glisson BS, Hong WK. Survival after treatment of small-cell lung cancer: an endless uphill battle. J Natl Cancer Inst. 1997 Dec 3; 89(23):1745-7. PMID: 9392609.
      View in: PubMed
    108. Shin DM, Glisson BS, Khuri FR, Ginsberg L, Lawhorn K, Hong WK, Lippman SM. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol. 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PMID: 9427263.
      View in: PubMed
    109. Lee JS, Pisters KM, Komaki R, Glisson BS, Khuri FR, Schea R, Fossella FV. Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-52-S12-55. PMID: 9331122.
      View in: PubMed
    110. Geara FB, Glisson BS, Sanguineti G, Tucker SL, Garden AS, Ang KK, Lippman SM, Clayman GL, Goepfert H, Peters LJ, Hong WK. Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. Cancer. 1997 Apr 1; 79(7):1279-86. PMID: 9083147.
      View in: PubMed
    111. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997 Jan; 15(1):310-6. PMID: 8996158.
      View in: PubMed
    112. Garden AS, Lippman SM, Morrison WH, Glisson BS, Ang KK, Geara F, Hong WK, Peters LJ. Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. Int J Radiat Oncol Biol Phys. 1996 Dec 1; 36(5):1005-12. PMID: 8985020.
      View in: PubMed
    113. Perez-Soler R, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM, Hong WK. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol. 1996 Oct; 14(10):2785-90. PMID: 8874340.
      View in: PubMed
    114. Glisson BS, Hong WK. Primary chemotherapy of advanced head and neck cancer: where do we go from here? J Natl Cancer Inst. 1996 May 1; 88(9):567-8. PMID: 8609650.
      View in: PubMed
    115. Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996 Feb; 14(2):503-13. PMID: 8636764.
      View in: PubMed
    116. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol. 1995 Mar; 13(3):645-51. PMID: 7884425.
      View in: PubMed
    117. Komaki R, Shin DM, Glisson BS, Fossella FV, Murphy WK, Garden AS, Oswald MJ, Hong WK, Roth JA, Peters LJ, et al. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys. 1995 Feb 15; 31(4):807-11. PMID: 7860392.
      View in: PubMed
    118. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 1994 Jun; 12(6):1238-44. PMID: 7911160.
      View in: PubMed
    119. Fisk B, Ioannides CG, Aggarwal S, Wharton JT, O'Brian CA, Restifo N, Glisson BS. Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line. Lymphokine Cytokine Res. 1994 Apr; 13(2):125-31. PMID: 8061113.
      View in: PubMed
    120. Lippman SM, Glisson BS, Kavanagh JJ, Lotan R, Hong WK, Paredes-Espinoza M, Hittelman WN, Holdener EE, Krakoff IH. Retinoic acid and interferon combination studies in human cancer. Eur J Cancer. 1993; 29A Suppl 5:S9-13. PMID: 8260265.
      View in: PubMed
    121. Glisson BS, Alpeter MD. Multidrug resistance in a small cell lung cancer line: rapid selection with etoposide and differential chemosensitization with cyclosporin A. Anticancer Drugs. 1992 Aug; 3(4):359-66. PMID: 1330082.
      View in: PubMed
    122. Lee JS, Libshitz HI, Fossella FV, Murphy WK, Pang AC, Lippman SM, Shin DM, Dimery IW, Glisson BS, Hong WK. Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer. J Natl Cancer Inst. 1992 Jul 1; 84(13):1039-40. PMID: 1318977.
      View in: PubMed
    123. Glisson BS, Killary AM, Merta P, Ross WE, Siciliano J, Siciliano MJ. Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids. Cancer Chemother Pharmacol. 1992; 31(2):131-8. PMID: 1333369.
      View in: PubMed
    124. Zatopek NK, Holoye PY, Ellerbroek NA, Hong WK, Roth JA, Ryan MB, Komaki R, Pang AC, Glisson BS. Resectability of small-cell lung cancer following induction chemotherapy in patients with limited disease (stage II-IIIb). Am J Clin Oncol. 1991 Oct; 14(5):427-32. PMID: 1659177.
      View in: PubMed
    125. Lee JS, Libshitz HI, Fossella FV, Murphy WK, Pang AC, Lippman SM, Shin DM, Dimery IW, Glisson BS, Hong WK. Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer. Cancer. 1991 Sep 1; 68(5):959-64. PMID: 1655220.
      View in: PubMed
    126. Holoye PY, Glisson BS, Lee JS, Dhingra HM, Murphy WK, Umsawasdi T, Levy JK, Jeffries D, Raber MN, Hong WK. Ifosfamide with mesna uroprotection in the management of lung cancer. Am J Clin Oncol. 1990 Apr; 13(2):148-55. PMID: 2156418.
      View in: PubMed
    127. Holoye PY, McMurtrey MJ, Mountain CF, Murphy WK, Dhingra HM, Umsawasdi T, Glisson BS, Lee JS, Carr DT, Valdivieso M, et al. The role of adjuvant surgery in the combined modality therapy of small-cell bronchogenic carcinoma after a chemotherapy-induced partial remission. J Clin Oncol. 1990 Mar; 8(3):416-22. PMID: 2307986.
      View in: PubMed
    128. Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol. 1989 Jul; 7(7):916-22. PMID: 2544685.
      View in: PubMed
    129. Kim HK, Zwelling LA, Sacks PG, Hong WK, Chan D, Silberman L, Glisson BS. Effect of retinoic acid on DNA cleavage and cytotoxicity of topoisomerase II-reactive drugs in a human head and neck squamous carcinoma cell line. Cancer Res. 1989 Mar 1; 49(5):1197-201. PMID: 2537145.
      View in: PubMed
    130. Holoye PY, Carr DT, Dhingra HM, Glisson BS, Lee JS, Murphy WK, Umsawasdi T, Jeffries D. Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma. Invest New Drugs. 1988 Sep; 6(3):217-8. PMID: 2847992.
      View in: PubMed
    131. Edwards CM, Glisson BS, King CK, Smallwood-Kentro S, Ross WE. Etoposide-induced DNA cleavage in human leukemia cells. Cancer Chemother Pharmacol. 1987; 20(2):162-8. PMID: 2822274.
      View in: PubMed
    132. Sullivan DM, Chow KC, Glisson BS, Ross WE. Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents. NCI Monogr. 1987; (4):73-8. PMID: 2819735.
      View in: PubMed
    133. Glisson BS, Ross WE. DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther. 1987; 32(2):89-106. PMID: 3037573.
      View in: PubMed
    134. Glisson BS, Sullivan DM, Gupta R, Ross WE. Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase. NCI Monogr. 1987; (4):89-93. PMID: 2819738.
      View in: PubMed
    135. Sullivan DM, Glisson BS, Hodges PK, Smallwood-Kentro S, Ross WE. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry. 1986 Apr 22; 25(8):2248-56. PMID: 3011082.
      View in: PubMed
    136. Glisson B, Gupta R, Hodges P, Ross W. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. Cancer Res. 1986 Apr; 46(4 Pt 2):1939-42. PMID: 3004712.
      View in: PubMed
    137. Glisson B, Gupta R, Smallwood-Kentro S, Ross W. Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res. 1986 Apr; 46(4 Pt 2):1934-8. PMID: 3004711.
      View in: PubMed
    138. Ross W, Rowe T, Glisson B, Yalowich J, Liu L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res. 1984 Dec; 44(12 Pt 1):5857-60. PMID: 6094001.
      View in: PubMed
    139. Glisson BS, Smallwood SE, Ross WE. Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells. Biochim Biophys Acta. 1984 Oct 5; 783(1):74-9. PMID: 6477925.
      View in: PubMed
    140. Wozniak AJ, Glisson BS, Hande KR, Ross WE. Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Res. 1984 Feb; 44(2):626-32. PMID: 6318974.
      View in: PubMed
    141. Erratum. Cancer. 118:6301.
    142. Nasopharyngeal Carcinoma in Non-endemic Populations. 113-132.
    143. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 7:23227-23238.
    144. Erratum. Journal of Thoracic Oncology. 6:1281.
    145. Nasopharyngeal Carcinoma in Nonendemic Populations. 131-150.
    146. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer. The Lancet Oncology. 18:42-51.
    147. Local and systemic strategies for gene replacement for cancer. British Journal of Cancer. 78:142.
    148. Head and neck cancer. 271-293.
    149. Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer. Seminars in Oncology. 24.
    150. MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. Current Opinion in Oncology.
    151. Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy. Head and Neck.
    152. Erratum. Cancer. 118:2560.
    153. Head and neck cancer. Current Opinion in Oncology. 13:167.
    154. Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung cancer. Clinical Cancer Research. 22:1674-1686.
    155. Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. Head and Neck.
    156. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head and Neck. 37:644-649.
    157. Multidrug resistance mediated through alterations in topoisomerase II. Cancer Bulletin. 41:37-40.
    158. Head and neck cancer. Current Opinion in Oncology. 12:205-206.
    159. Characterization of epipodophyllotoxin resistance in VPM-5 mutant CHO cells.
    GLISSON's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description